Senior Advisor, Smed Advisory
2026 -
Own advisory practice, Hellerup
Advice on strategy, execution and AI for companies in health and life science. smedadvisory.dk
Mentoring a Danish startup, AI for clinical documentation
Through DTU Skylab I mentor the founders, on the commercial side. In that period the company has achieved:
- Customers: customer base up more than 30%.
- New market: the product taken into a new vertical, psychiatry.
- Partnerships: two partnerships with integration into the IT systems Danish general practice runs on.
- Commercial groundwork: grant application, pitch deck, strategy document, financial model, commercial funnel, and a social media and ads plan in place.
VP, Digital, Strategy & Bioethics
2023 - 2026
Novo Nordisk, Research & Early Development. Måløv, Denmark
- Level
- CEO-3. Reported to the SVP. Member of the area leadership team and executive office for the SVP.
- Team
- About 40 people in 3 teams across EU, UK and Asia. 2 leaders of leaders and 6 other direct reports, including the VP of Digital I hired.
- Budget
- DKK 40M a year in my own budget. Seat on the DKK 200-250M Data & Digital Investment Group. Business owner of resource allocation across 2,800 people.
Strategy and execution, and the AI, digital, data and bioethics agenda for the SVP's area: the 3-year roadmap, the priorities behind it, and getting them into the line.
- Transformation: drove the restructuring of the SVP's 800-person area after 2 units were merged. New operating model, governance from preclinical to Phase 2, roles and responsibilities redesigned across Research. Best in class employee satisfaction afterwards.
- Portfolio decisions: as a member of the investment committee, helped reprioritise a DKK 200-250M annual pool with a 4-category model. About 30% moved to the highest-value projects at twice the speed to milestone, with the backing of the people whose projects were closed.
- AI and digital: scaled research data and AI platforms to 65%+ adoption across the 2,800-person research area. Chat-based AI proofs of concept and AI training with completion tracked.
- Governance: built the EU AI Act framework (classification, risk assessment, System Impact Assessment) into the vendor evaluation itself. NIS2 accountability across 2,800 people. Seat on the Data, AI and Business Ethics board.
- Data foundation: a data quality and governance programme with named data owners and stewards, so AI use cases became possible. 40+ ambassadors, 30+ completed initiatives, satisfaction above 4.5 of 5.
VP, Integrated Treatment Solutions
2022 - 2023
Novo Nordisk, Corporate Strategy. Bagsværd, Denmark
- Level
- CEO-3. Reported to the SVP. Member of the area leadership team.
- Team
- Core team of 5. Steering group across 6 SVP areas.
Start a new business area next to the existing treatment business: find the company's way into prevention and make it commercially worth engaging in.
- Alignment: agreement across 6 SVP areas (Development, Commercial and Device) on a single integrated treatment model, taking the disagreements 1:1 before any joint meeting.
- Result: the work became the Transformational Prevention Unit, with a budget above DKK 100M a year.
Global VP, Head of Digital Health
2018 - 2022
Novo Nordisk, Commercial Strategy & Corporate Affairs. Søborg, Denmark
- Level
- CEO-3. Reported to the SVP. Chair of the company-wide Digital Health Steering Committee.
- Team
- About 200 in the organisation. 40 reported directly to me in 5 teams, the rest dotted line. Leadership team of 6 covering partnerships, data and strategy, commercial strategy, products, public affairs and finance.
- Budget
- Above DKK 200M a year. Data owner for the enterprise data lake.
Mandate from executive management to own all digital health development and commercial activity globally, and to build the franchise, the products and the partner model from nothing.
- Build and scale: first Software as a Medical Device franchise in big pharma. CE marked class 1, 2A and 2B and FDA cleared products, including NovoPen 6, DoseGuide and DoseCheck. 100,000 users and 1 billion data points by 2022.
- Strategy: 10-year business plan approved by executive management, anchored on how far into patient care a pharma company should go.
- Partnerships: 7+ global medtech companies and 30+ startups on a non-monetary, data-exchange model, the first in pharma. Joint steering committees with Abbott, Dexcom, Medtronic, Glooko and Dawn Health.
- Evidence: Phase 3 trial with DoseGuide, a Swedish real world study of 2,500+ patients, 6 peer-reviewed publications.
- Execution: SaMD quality management system, AWS platform and SAFe delivery model with 5+ teams, built and run as accountable business owner.
Senior Director and Director, Head of Digital Health Commercial Strategy
2018
Novo Nordisk, Strategy, Access & Marketing. Søborg, Denmark
- Team
- 5 people in January. Leader of leaders from March: 8 specialists and 1 people manager.
Take over the digital health commercial strategy area, rebuild it after a bad year, and set the direction for a digital health business.
- Turnaround: took over one of the areas with the lowest employee satisfaction in the company, 2.8 of 5. Kept every person. 5.0 of 5 when measured again later that year.
- Promoted: to Senior Director after 3 months and to VP after 8 more.
Director, Executive Office
2015 - 2018
Novo Nordisk, Marketing & Region Pacific, then Commercial Strategy & Corporate Affairs. Søborg, Denmark
- Level
- CEO-2. Reported to the EVP, in Executive Management. Chief of staff to 2 EVPs.
- Team
- 8 people across business ethics, quality assurance, internal communication, events and area finance. First people manager role.
Run the executive office, and land the restructurings and build-outs the EVPs needed. Secretariat for the Product Management Committee, taking multi-billion DKK investment decisions across products, devices and production capacity.
- Build and scale: started the Bangalore commercial hub. Rewrote SOPs and workflows so whole workflows could move, made the first 5 to 10 hires. Today 300+ people.
- Transformation: ran global restructurings of commercial roles and responsibilities for 2 EVPs, directing teams from top tier consultancies.
- People: brought a team member back from stress leave to high performance within a year. She now heads quality at another pharma company.
Product, portfolio and launch
2005 - 2015
Novo Nordisk, Global Marketing and Operations & Product Supply. Five roles.
2013 - 2015Senior Global Project Manager, Launch StrategyBuilt the global launch framework still in use. Launch preparation for 20 to 30 affiliates on Tresiba, Xultophy and Ryzodeg.
2011 - 2013Global Portfolio Manager, New Product PlanningeNPV and portfolio analyses with the project VPs. Chaired the Early Commercial Team for a GLP-1/glucagon programme.
2010 - 2011Global Product Manager, Future DevicesCommercial lead on connected injection devices. Wrote the Treatment Insights strategy, the precursor to Digital Health.
2007 - 2010Global Product Manager, Devices Brand TeamGrew a USD 200M needle business 20% in a market growing 10%. Launched NovoTwist and NovoFine Autocover.
2005 - 2007Business Process Graduate ProgrammeMarketing effectiveness on a USD 100M glucagon business, PMO on the AERx programme in California, competitor intelligence in R&D.